## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.7% below STRENGTH zone (4.0-10.0%); PEG 4.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Edwards Lifesciences Resolves $140 Million Harpoon Medical Case**
- Source: Bloomberg Law News | 20251215T171309 | Neutral | Relevance: 100%
- Edwards Lifesciences Corp. has resolved a lawsuit seeking up to $140 million related to its acquisition of Harpoon Medical Inc. The dispute involved claims from former Harpoon investors that Edwards failed to commercialize a heart valve device. The terms of the settlement, which scuttled a planned trial, were not disclosed.

**2. 934,449 Shares in Edwards Lifesciences Corporation $EW Bought by Hudson Bay Capital Management LP**
- Source: MarketBeat | 20251214T130816 | Somewhat-Bullish | Relevance: 100%
- Hudson Bay Capital Management LP has acquired a new position of 934,449 shares in Edwards Lifesciences (NYSE:EW) during the second quarter, valuing the stake at approximately $73.1 million. This makes Edwards Lifesciences the 25th-largest holding for Hudson Bay, representing about 0.16% ownership of the company. The company recently exceeded quarterly expectations with $0.67 EPS and $1.55 billion in revenue, and analysts currently rate the stock as a "Moderate Buy" with a mean price target of $93.30.

**3. Holocene Advisors LP Buys 1,223,460 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251214T130815 | Somewhat-Bullish | Relevance: 100%
- Holocene Advisors LP significantly increased its stake in Edwards Lifesciences (NYSE:EW) by 35.2%, acquiring an additional 1,223,460 shares, bringing its total holdings to 4,703,977 shares valued at approximately $368 million. This makes Edwards Lifesciences the 18th largest position in Holocene Advisors LP's portfolio. Despite this institutional buying, company insiders have been net sellers, liquidating 45,465 shares ($3.8 million) in the last 90 days.

**4. Elevatus Welath Management Makes New Investment in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251213T112907 | Bullish | Relevance: 100%
- Elevatus Wealth Management has acquired a new stake of 31,890 shares in Edwards Lifesciences (NYSE:EW), valued at approximately $2.49 million, during the second quarter. Institutional investors now collectively own about 79.46% of the company's stock, while analysts maintain a "Moderate Buy" consensus rating with a target price of $93.30. Despite positive earnings and revenue, insiders have sold a significant number of shares recently.

**5. Banque Transatlantique SA Purchases 24,575 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251213T093039 | Somewhat-Bullish | Relevance: 100%
- Banque Transatlantique SA increased its stake in Edwards Lifesciences Corporation by 79.3% in the second quarter, acquiring an additional 24,575 shares, bringing its total holdings to 55,568 shares valued at $4,361,000. This move aligns with other institutional investors adjusting their positions in the medical research company, even as analysts maintain a "Moderate Buy" rating with an average price target of $93.30. Recent insider selling has also been noted, with executives divesting a significant number of shares.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $101 | $96 | +5% |
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.7x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 10 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.75 signals overvaluation risk, limited margin of safety. Forward P/E 28.9x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $48.8B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.75 |
| Forward P/E | 28.9 |
| Current P/E | 32.2 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 6.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-0.51), momentum weakening. RSI neutral at 47. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.66% (CS: 17) | Weak |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 0.977x | Below |
| vs SMA50 | 1.020x | Above |
| vs SMA200 | 1.079x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.08
- **Stop Loss:** $79.56 (4.2% risk)
- **Target:** $86.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 284
- **Position Value:** $23,594.72
- **Portfolio %:** 23.59%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*